CA05156V1022
CA05156V1022
Aurinia Pharmaceuticals Inc
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | 283.055.000 | 235.133.000 | 20.4% |
| Cost of Revenue | 32.665.000 | 28.248.000 | 15.6% |
| Gross Profit | 250.390.000 | 206.885.000 | 21.0% |
| 143.829.000 | 188.466.000 | 23.7% | |
| Operating Income | 106.561.000 | 18.419.000 | 478.5% |
| Pretax Income | 114.157.000 | 7.448.000 | 1432.7% |
| Net Income Common Stockholders | 287.202.000 | 5.752.000 | 4893.1% |
| -- | -- | -- | |
| -- | -- | -- |